Galectin Therapeutics Inc

Insider buying at Galectin Therapeutics signals confidence as belapectin data sparks a 7 % weekly gain—watch key milestones and capital moves for upside.

Insider sale at Galectin Therapeutics reveals CEO liquidity needs and raises questions on future strategy, but the company’s key clinical milestones and competitive landscape remain critical for its valuation and growth.